Skip to main content
Equibles
PRGO logo

PRGO · PERRIGO Co plc

Track PRGO — free

Use PRGO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRGO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.04 +0.21 (+1.64%) At close · Aug 14
Market Cap
$1.81B
Shares
138.77M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.04 Open$12.72 Day$12.61–13.06 52W close$9.25–24.49 Avg vol 30d3.0M Short int23.1M · 16.7% float · 8.3d Short vol56% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +5%
      above
      Price vs 50-day avg +20%
      above
      RSI (14) 67
      neutral
      MACD trend Positive
      52-week position 25%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +22%
      trailing
      6-month return −10%
      trailing
      YTD return −6%
      this year
      Relative strength −24%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $12 — 200d above 50d
      Institutional flow Accumulating
      +0% holders QoQ · +71 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      16.68% of float · ▲ +0.9% MoM · 8.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      331 holders — near 3-yr low, contrarian setup
      Squeeze score 77
      high risk · 0–100
      Fundamentals
      Strong
      Gross margin 186813%
      EPS growth −723%
      Y/Y
      Free cash flow $145.1M
      Buyback $835.8M
      remaining
      Balance sheet $3.1B
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 54%
      annualized · 1-yr
      Max drawdown −62%
      past year
      ATR 4.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Mar 31, 2026
      2026
      Operational enhancement program cost savings Non-GAAP $60M – $80M
      2027
      Operational enhancement program cost savings Non-GAAP $20M – $40M
      Prior guidance period ended · from the 8-K filed Nov 5, 2025
      Net sales growth · Full Year 2025 -3% – -2.5%
      Adjusted gross margin · fiscal year 2025 39%
      Reported net sales growth · fiscal year 2025 -3% – -2.5%
      Organic net sales growth · fiscal year 2025 -2.5% – -2%
      Adjusted operating margin · fiscal year 2025 15%
      Interest expense · fiscal year 2025 $155M
      Adjusted diluted EPS · fiscal year 2025 $2.70 – $2.80
      Adjusted effective tax rate · fiscal year 2025 18.5%
      Infant formula business net sales · 2025 $360M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +5% Bullish
      Price vs 50-day avg
      +20% Bullish
      RSI (14)
      67 Neutral
      MACD trend
      Positive Bullish
      52-week position
      25% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $11 › 200d $12 — 200d above 50d
      Institutional flow Accumulating
      +0% holders QoQ · +71 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      16.68% of float · ▲ +0.9% MoM · 8.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      331 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $9 Now $13 · 25% Range high $24
      vs 200-day avg +5% vs 50-day avg +20%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted gross margin non-GAAP 35.6% Three Months Ended June 27, 2026 —
      Adjusted gross profit non-GAAP $364.5M Three Months Ended June 27, 2026 —
      Adjusted income from continuing operations non-GAAP $70.3M Three Months Ended June 27, 2026 —
      Adjusted operating income non-GAAP $124.5M Three Months Ended June 27, 2026 —
      All In Adjusted Diluted EPS non-GAAP $0.5 2Q'26 —
      All In Adjusted Gross Margin non-GAAP 35.6% 2Q'26 —
      All In Adjusted Operating Margin non-GAAP 12.2% 2Q'26 —
      All In Organic Net Sales non-GAAP $1.02B 2Q'26 —
      Constant currency net sales non-GAAP $1.02B Three Months Ended June 27, 2026 —
      Core Adjusted Diluted EPS non-GAAP $0.46 2Q'26 —
      Core Adjusted Gross Margin non-GAAP 37% 2Q'26 —
      Core Adjusted Operating Margin non-GAAP 13% 2Q'26 —
      Core Organic Net Sales non-GAAP $903M 2Q'26 —
      Organic net sales non-GAAP $1.02B Three Months Ended June 27, 2026 —
      Segment operating income: Infant Formula non-GAAP $4M 2Q'26 —
      Segment operating income: Self Care non-GAAP $79M 2Q'26 —
      Segment operating income: Specialty Care non-GAAP $48M 2Q'26 —
      Total segment operating income non-GAAP $131M 2Q'26 —
      Segment adjusted operating income: Infant Formula non-GAAP $9.6M Twelve Months Ended December 31, 2025 —
      Segment adjusted operating income: Self Care non-GAAP $472.6M Twelve Months Ended December 31, 2025 —
      Segment adjusted operating income: Specialty Care non-GAAP $200.5M Twelve Months Ended December 31, 2025 —
      Total segment adjusted operating income non-GAAP $682.6M Twelve Months Ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PRGO
      PERRIGO Co plc
      this stock
      		$1.81B -6.3% +0.0% — 16.7%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.49B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      331
      % held
      117.1%
      Net QoQ
      +10.1M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      105
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      23.1M
      Days to cover
      8.3d
      Change
      +214.0K sh
      View
      Short Volume
      Short vol %
      56%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      42.3K
      Value
      $432.8K
      As of
      Jul 13, 2026
      View
      Off-Exchange
      Off-exchange %
      40.9%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      Mar 18, 2020
      View
      Financials
      Financials
      Revenue (FY)
      $4.3B
      Net income (FY)
      $-1.4B
      EPS diluted
      $-10.29
      View
      Buybacks
      Authorized
      $1.0B
      Remaining
      $835.8M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $164.2K
      Shares
      14.4K
      Filed
      May 28, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PRGO +1.6% +21.6% -10.4% +29.0% -6.3%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +1.2% +17.2% -24.2% +25.1% -20.2%

      Capital returns

      Latest dividend
      $0.29 / share · ex May 29, 2026
      Declared · upcoming
      $0.29 / share · ex Aug 28, 2026
      Raised 5.1%
      Paid (TTM)
      $0.87 / share · 3 payouts
      Dividend yield (TTM, derived)
      6.67%
      Buyback program · as of Dec 31, 2025
      Authorized
      $1.00B
      Spent (derived)
      $164.20M
      Remaining
      $835.80M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1585364 CUSIP G97822103 13F (30d) 339 filings 305 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)